Home
Career Stage
Medical Students Residents Attendings CPT Codes Resources Blog Support

J3392 Injection, exagamglogene autotem

J Codes (Drugs)

Also known as: exagamglogene autotemcel, Strimvelis, ex vivo gene therapy

Exagamglogene autotemcel (Strimvelis) injection is a gene therapy for adenosine deaminase-deficient severe combined immunodeficiency.

In Plain Language

immune system gene therapy; severe immunodeficiency treatment

Clinical Context

Gene therapy for adenosine deaminase-deficient severe combined immunodeficiency. Autologous T cells modified with adenosine deaminase gene. Intravenous administration to reconstitute immune function.

RVU Information

CPT J3392 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.

Billing & Documentation

J-codes represent drugs administered by a healthcare provider (not self-administered). Documentation must include the drug name, dosage, route of administration, and medical necessity. Most payers require the National Drug Code (NDC) on the claim. Bill the appropriate administration code (96365-96379) in addition to the drug code.

Specialties

ImmunologyHematologyGene Therapy

Frequently Asked Questions

What is CPT code J3392?

CPT J3392 (Injection, exagamglogene autotem) is a J Codes (Drugs) code. Exagamglogene autotemcel (Strimvelis) injection is a gene therapy for adenosine deaminase-deficient severe combined immunodeficiency.

How is J3392 administered?

CPT J3392 is administered by a healthcare provider, typically via injection or infusion. Gene therapy for adenosine deaminase-deficient severe combined immunodeficiency. Autologous T cells modified with adenosine deaminase gene. Intravenous administration to reconstitute immune function. It is used by Immunology, Hematology, Gene Therapy.

When is CPT J3392 used?

Gene therapy for adenosine deaminase-deficient severe combined immunodeficiency. Autologous T cells modified with adenosine deaminase gene. Intravenous administration to reconstitute immune function.

Track This Code in RVU Edge

Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.

CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.